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ABSTRACT

SA-4-IBBL AS A MODULATOR OF T EFFECTOR TO T REGULATORY CELL
CONVERSION
Shravan Madireddi
July 22,2010
The immune system is of profound importance for host survival due to its ability
to clear many acquired diseases. In case of infections and cancer, disease arises due to
under-performance of immune system. Whereas in autoimmunity and transplantation,
deleterious immunity to normal self-antigens and allogeneic antigens arises due to
enhanced immune responses. Regulatory T (Treg) cells play a critical role in immune
homeostasis in health and disease.
Treg cells are important in the development and maintenance of immune
tolerance towards self or transplantation antigens. However, Treg cells also play an
obstructive role in cancer-related immunity by suppressing various effector cells.
Therefore, development of immunomodulatory approaches that can either promote or
inhibit expansion and/or suppressive function of Treg cells in the context of
autoimmunity/transplantation and cancer/chronic infections, respectively, is of great
importance. Treg cells require three signals, mediated by TCR-MHC-II1peptide (Signal
1), co stimulation (signal 2) and cytokines (signal 3), for development, maintenance and
function.

Manipulation of any of these signals, therefore, may present an effective

approach in modulating Treg cells in the context of various disease settings. The goal of
VI

this dissertation is to exploit signal 2 for modulating Treg cells in the setting of cancer
and transplantation for immunotherapy.

We chose the 4-1 BB signaling pathway because of its constitutive expression on
Treg cells and its important role in both innate and adaptive immunity. Using a chimeric
4-1BBL (SA-4-1BBL), we herein show that signaling through 4-1BB inhibits antigen and
TGF-~

driven conversion of Teff into Treg cells. This effect is primarily mediated by

SA-4-IBBL-induced IFN-y production in Teff cells. Importantly, vaccination of mice
with established ovalbumin (TAA) expressing EG.7 tumors with SA-4-1BBL results in
the blockade of Teff cell conversion into Treg cells within the tumor and spleen. In
contrast, SA-4-1BBL in the presence of IL-2 and rapamycin promotes the conversion of
naIve CD4+ T cells into Treg cells.

Provision of three signals (allogeneic TCR

stimulation, 4-1BBL mediated co-stimulation, and IL-2 cytokine) in the presence of
rapamycin was effective in enhancing the generation/expansion of Treg cells. This is
unique to 4-1BB as signaling through CD28 did not increase the generation of Treg cells.
Collectively, these novel functions of soluble form of SA-4-1 BBL represent a promising
approach to inhibit/promote Treg cell generation/expansion with potential therapeutic
applications in cancer immunotherapy and transplantation.
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CHAPTER!
INTRODUCTION

Regulation of immune system is of profound importance to host survival. In
settings of autoimmunity or cancer, control is lost, resulting in hyper or hypo activation
of immune system respectively. Suppression of deleterious immunity to normal selfantigens in autoimmune diseases, establishment of immunological tolerance to allogeneic
transplants and reversal of the unresponsive state and enhancing immune responses to
autologous tumor cells or chronic infections are essential for effective immunotherapy.
Regulatory T (Treg) cells play an essential role in the establishment and maintenance of
peripheral tolerance (1). There is now convincing evidence that defect in the numbers
and/or function of Treg cells can lead to autoimmunity and graft rejection, whereas an
excess of Treg cells can inhibit anti-tumor and anti-pathogen immunity (1-8). Therefore,
there is an immediate need for the development of immunomodulatory approaches that
can promote expansion of Treg cells in the context of autoimmunity and transplantation
and also inhibit the expansion and/or suppressive function of Treg cells in the context of
cancer and chronic infections. Signaling pathways required for the regulation of Treg
cells might represent efficient targets for designing Treg cell-based immumodulatory
approaches for the treatment of these diseases.
These

are

signal

1 delivered

via T-cell

receptor (TCR)

and

major

histocompatibility complex (MHC) molecules/peptide interactions, which needs
1

to be accompanied by costimulation delivered via CD28 receptor family (9). Treg cells
than get activated and need cytokines, particularly IL-2, for expansion and acquisition of
effector function (10). A series of recent studies, including those from our laboratory,
have demonstrated that several members of the tumor necrosis receptor (TNFR) family
can provide co stimulation to Treg cells for their expansion and survival (11-13).

In

particular, we demonstrated that costimulation via 4-1 BB receptor has diverse functions
on Teff and Treg cells with therapeutic implications in cancer, transplantation, and
autoimmunity (12-16). Thus the aim of this dissertation is to exploit 4-1BB/4-1BBL
signaling as a novel immunomodulatory approach for manipulating Treg cells m an
attempt to modulate immune responses in cancer and transplantation settings.

The

rationale for focusing on 4-1BB/4-1 BBL pathway is because of its critical role in
regulating both T effector (Teff) and Treg cell responses that can be tuned for the
treatment of disease. In the case of cancer or infectious diseases, preferential reduction of
Treg cell numbers and/or blocking their function may enhance antitumor/pathogen
immunity. However, in case of transplantation, preferential augmentation of Treg cell
numbers and/or function may help suppress autoimmune responses and facilitate the
establishment of tolerance to allogeneic antigens.

Regulatory T cells

The primary function of the immune system is to protect the body from foreign
pathogens. This requires the immune system to recognize a countless number of antigens
along with its ability to differentiate between self and non-self (17). Thymus plays a
critical role in generating an extensive repertoire of T cells to recognize these antigens by
positive selection based on TCR avidity (18). Along with that, a passive central tolerance
2

mechanism also exists in the thymus where self reactive cells are deleted by a process
called clonal deletion or negative selection (19). However, self reactive T cells escape
into the periphery and exist in healthy individuals without causing autoimmune diseases.
This is because several regulatory mechanisms, such as clonal deletion (20), anergy (21)
and suppressive cytokines (22) exist in the periphery to keep in check the pathogenic selfreactive T cells.
In addition to these acquired peripheral tolerance mechanisms, the presence of
natural tolerance through a T cell population called naturally occurring T regulatory
(nTreg) cells, identified by the expression of CD4 and FoxP3 markers, has been
established (1). These cells play a critical role in self tolerance as demonstrated by the
presence of severe and uncontrolled autoimmunity in mice and patients that lack these
cells (23-27). Although the primary function of these cells in the periphery is to control
self-reactive pathogenic Teff cell function and collateral damage as a result of
uncontrolled immune responses to infections, thereby contributing to immune
homeostasis, a series of published evidence indicate that Treg cells can contribute to
disease by either positively or negatively affecting the ongoing immune responses such as
in cancers and autoimmunity, respectively (3, 5, 7, 28-36).
nTreg cells are selected and generated in the thymus through high avidity
interactions between MHC class II and TCR (10, 37-42). The first evidence that nTreg
cells are selected in the thymus came from studies demonstrating the existence of a subset
of CD25+ cells in the CD4 single-positive thymocyte compartment in thymus of both
humans and mice (43-45). These CD25+CD4+ thymocytes were capable of suppressing
the function of Teff cells in vitro as well as in vivo in adoptive transfer models (43).
Importantly, these cells under normal physiological conditions also exhibited increased
3

expression of various activation markers, such as CTLA-4, GITR, Pas, and OX-40 (44,
46) that are normally expressed on activated Teff cells, suggesting that Treg cells may
always be in a semi-activated phenotype, plausibly due to constant control of potential
autoreactive effector peripheral mechanisms.
TCR signaling is indispensable for T cell lineage commitment of Treg cells
The role of TCR in the development of

during their development in the thymus.

Treg cells is best demonstrated by the finding that TCR-transgenic mice on RAG-1background (recombination-activating gene-deficient mice which lack endogenous TCR
rearrangements) do not develop Treg cells, whereas most TCR-transgenic mice on nonRAG- 1- background develop Treg cells (18, 47).

Apart from TCR signaling,

costimulatory signals mediated by CD28/CD80 or CD86 are important in determining the
repertoire and size of the Treg cell compartment in the periphery even though this
signaling is not required for their function (9). Mice lacking either CD28 or CD80 and
CD86 have decreased Treg cells in the periphery (9).

This decreased Treg cell

compartment is attributed to the direct role of CD28 signaling on thymocyte development
of Treg cell and also due to diminished peripheral IL-2 produced by T cells in the
absence of CD28 co stimulation (48). Apart from TCR and CD28 signaling, dependence
of Treg cells on IL-2 has been linked to their development, maintenance, survival and
expansion of the Treg cell population (49).

Deficiencies in either IL-2 or IL-2R is

manifested by severe autoimmune disorders marked by excessive lympho proliferation
(50). However, adoptive transfer of splenic or thymic CD4+ T cells from IL-2-deficient
mice, but not from CD25-deficient mice, into a TCR-transgenic model of experimental
allergic encephalomyelitis (EAE) showed that these Treg cells can protect from
developing EAE. Thus, it suggests that Treg cell can development and undergo lineage
4

commitment in the thymus in the absence of IL-2. However, signaling through IL-2
receptor is essential for their activity.
Both humans and mice develop a fatal autoimmune disorder (immune
dysregulation, polyendocrinopathy, enteropathy, X-linked - IPEX in humans and scurfy
in mice) due to mutations in the gene encoding FoxP3 transcription factor, strengthening
the importance of this molecule in the development/function of Treg cells (24, 27, 51,
52). In humans, this immune disorder is marked by massive lymphoproliferation, onset
of Type 1 Diabetes, thyroiditis and food allergies. Additionally, some patients develop
other autoimmune pathologies like hemolytic anemia and thrombocytopenia, eczema,
severe enteropathy as well as severe infections (51).

Scurfy mutant mice lacking

functional FoxP3 do not develop Treg cells and show various autoimmune pathologies
(53, 54). FoxP3 protein belongs to a family of transcription factors that display a similar
domain called winged helix-forkhead DNA-binding domain (forkhead box - Fox).
FoxP3 transcriptional factor bind to the promoter DNA of various genes, acting as a
transcriptional regulator (most suppressor) for various cytokines such as IL-2, IL-4 and
TNF (55). In the absence of other cell surface molecules that are specific for Treg cells,
FoxP3 expression is used as the sole marker for the identification of Treg cells for mice.
However, this is not the case for human as newly activated human Teff cells also
transiently express FoxP3 (56-60) and as such the identification of human Treg cells
require testing their suppressive function for confirmation.
The role of nTreg cells in the maintenance of peripheral tolerance has been
extensively studied.

This is illustrated by spontaneous development of autoimmune

diseases by the depletion of Treg cells in normal animals and restoration of these cells in
tum prevents the development of the disease (1, 61). For example, Treg cell depleted
5

spleen cells from nonnal mice cause spontaneous autoimmune disease in multiple organs
following

adoptive

transfer

into

syngeneic

T-cell-deficient

hosts

(62-64).

Functional/physical elimination of Treg cells in setting of cancer has therapeutic
implications (34). For example, depletion of C4+CD2S+ T cells before tumor challenge is
effective in eliciting potent tumor specific immunity in vivo along with the development
of various autoimmune diseases (34).

Thus, nTreg cells are not only effective in

inhibiting autoimmunity but also block/suppress a variety of physiological and
pathological immune responses to non-self antigens that manifest in acquired diseases.

In recent years, it became evident that in addition to nTreg cells that are generated
m the thymus, another population of CD4+FoxP3+ T cells with regulatory function
develop from the conversion of naIve CD4+ T cells outside the thymus under various
settings (6S-67). This so called adaptive or induced (iTreg) cells behave in a similar
manner to the nTreg cells in suppressing immune responses. The first set of evidence for
the existance of this cell type came from adoptive transfer experiments where naIve
CD4+CD2S- T cells were transferred to lymphopenic mice or mice devoid of nTreg cells

(SO, 68). During the homeostatic expansion of the transferred cells, part of the population
acquired FoxP3 expression and suppressive function. Induction of iTreg cell in vivo by
foreign antigens was also shown in mice treated with minute antigen doses (6S). iTreg
cells can also be induced in vitro from naive CD4+ T cells, particularly in the presence of
TCR stimulation and TGF-~ and IL-2 cytokines (66, 69). Thus, it is clear that naive
CD4+ T cells selected

as

FoxP3- in the thymus have

full

potential

to

become

FoxP3+ iTreg cells in vivo and in vitro (Figure 1). These cells are critical to acquired
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peripheral tolerance as well as exploited for immune evasion by cancer and infections or
experimentally for tolerance to auto and alloantigens for therapeutic purposes.

Generation of iT reg cells

Unlike nTreg cells, which develop in a highly controlled thymic microenvironment (70),
generation of iTreg cells may vary based on the environmental cues or conditions. Initial
evidence of peripheral conversion came from adoptive transfer experiments where sorted
polyclonal naive CD4+CD2Y T cells transferred into lymphopenic mice or TCR
transgenic mice on RAG-1- background, which lack nTreg cells, were shown to convert
into FoxP3 expressing iTreg cells (50, 68). Under those settings, where homeostatic
proliferation of the transferred cells was possible, part of the donor population
became CD2S+ and FoxP3+ and they also expressed Treg cell specific markers CTLA-4
and GITR along with their suppressive capability.

In a different setting, transfer of

antigen-specific naive CD4+ T cells into lymphocyte-deficient RAG-1- mice that expressed
the antigen as a systemic secreted protein resulted in acute immune response from
transferred cells towards the recipient. This was followed by a tolerogenic phase that is
associated with iTreg cell generation (71). This iTreg cell generation did not require
the thymus but was dependent on IL-2.

Although the precise developmental

requirements of iTreg cell generation in vivo is still incomplete, some studies successfully
generated iTreg cells in vivo by treating mice with low doses of antigen cross-linked to
DEC-20S Ab (targets antigens specifically to DCs) and delivered by osmotic pump.
Conversion of CD4+CD2S- T cells into iTreg cells was also shown in another adoptive
transfer model where sorted CD4 cells were transferred into irradiated mice (72). Under
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these lymphophenic conditions, these cells readily underwent conversion and this was
independent of thymus, but was dependent ofCD28 signaling.

In vitro generation of iTreg cells reqUIres both TCR stimulation and the
cytokines TGF-~ and IL-2 are absolutely required for naYve CD4+ effector cells to
convert into iTreg cells.

During TCR-stimulation, addition

ofTGF-~

to naive

CD4+ T cells cultures induces the expression of FoxP3 (66) and the mechanism involves
cooperation of the transcription factors STAT3 and NF AT at a FoxP3 gene enhancer
element (69, 70). Addition

ofTGF-~

along with CD3 and CD28 stimulation to naive

CD4+ T cells induced the generation of iTreg cells which were anergic and suppressive in

vitro and in vivo as shown by their ability to suppress inflammation in an
experimental asthma model (66).

As discussed in the nTreg cells section, IL-2 is

dispensable for the generation of nTreg cells in the thymus.

However, for in vitro

generation of iTreg cells, IL-2 is required. Studies done by neutralization IL-2 in the
cultures or using IL-2-deficient T cells demonstrated that IL-2 is required for in vitro
for induction of FoxP3 mediated by

TGF-~

(73).

IL-2 signaling is required for the

activation of STAT5, which in tum binds to FoxP3 gene enhancing its expression.
Costimulatory signal mediated by CTLA-4 is dispensable for thymic generation of nTreg
cells (74). However, upregulation ofCTLA-4 is required for

TGF-~

mediated expression

of FoxP3 in naYve CD4+ T cells and also for suppressive activity of converted iTreg cells
(74).

Differences between nTreg and iTreg Cells

There has been some disagreement on whether in vitro generated iTreg cells are as good
suppressor cells as nTreg cells (28, 33, 66, 75-77). The functional difference between
8

nTreg cells and iTreg cells looks to arise from the methylation of CpG motifs in the
FoxP3 locus where nTreg cells have complete demethylation upstream of exon 1 and is
unique to FoxP3+ Treg cells. In contrast to nTreg cells, in vitro generated iTreg cells
display partial demethylation even though they have high FoxP3 expression (78). These

in vitro generated iTreg cells, but not nTreg cells, lost both FoxP3 expression and
suppressive activity when restimulated in the absence ofTGF-B (79, 80).

A marked

difference in the methylation state of iTreg cells generated in vitro and in vivo is that in

vivo iTreg cells generated by administration of antigen displayed efficient demethylation
(78) and are effective suppressors as compared to in vitro generated iTreg cells (65, 71,
81-83). Using gene profiling, studies have defined pool of genes that are specifically
expressed in nTreg cells. Some of these genes are regulated independently by FoxP3 and
some of them are repressed or induced exclusively by FoxP3 (76). Comparing this subset
of genes that are either upregulated or downregulated between nTreg cells and iTreg cells
showed that in vitro generated iTreg cells did not display some of the nTreg cell signature
genes (76).
As iTreg cells are generated in the periphery from naIve CD4+ T cells, nTreg and
iTreg cells might have potential differences in terms of TCR repertoire, differentiation
and their mode of action. Studies have indicated that iTreg cells mediate their inhibitory
function by producing immunosuppressive cytokines like TGF-B and IL-lO (84, 85).
Contrastingly, nTreg cells are shown to function by direct cell-cell interactions with
responding T cells or APCs and this mechanism is cytokine-independent (86).

9

iT reg cells and Cancer
Recent progress in understanding the ability of innate and adaptive immune responses
against tumors has strengthened the concept of immunosurveillance. For example, the
incidences of tumor in immune-incompetent individuals either via acquired genetic
defects or experimental/therapeutic manipulations are significantly higher than
individuals with normal functions (87).

Most importantly, a recent study has

demonstrated using a spontaneous mouse model of melanoma that tumor cells
disseminate throughout the body early in development of the primary tumor and stays
dormant for varying periods of time depending on the tissue.

Most importantly,

dormancy in the lung was associated with reduced proliferation of the disseminated
tumor cells by CD8+ T cells as physical elimination of these immune cells resulted in
accelerated tumor growth (88). Irrespective of active immunosurveillance, tumors grow
in immune-competent individuals suggesting that immune system and tumors exist in an
equilibrium state.

This is primarily due to the ability of tumors to exploit various

immune evasion mechanisms for growth and progression. This is evidenced by studies
demonstrating the presence of tumor-specific and activated both CD4+ and CD8+ T cells
in cancer patients without functional consequences with respect to clinical disease (89).
These observations suggest that immune system in patients with cancer is constantly on
attack, but there are other counter-attack mechanisms that tilt the balance towards
immune inactivation and tumor progression.

Tumors employ multiple mechanisms for evading T cells responses. Some of
these include alterations of components of the antigen presentation machinery, secretion
of inhibitory factors, activation of negative regulatory pathways, and recruitment of Treg
10

cell populations (90-93). Treg cells represent one of the most dominant immune evasion
mechanisms employed by tumors for progression. Increased numbers of Treg cells in
tumor tissue and/or peripheral blood of patients with various cancers have been reported
(2, 4, 35, 94, 95) and this is associated with poor prognosis and survival (2). Dominant
role of Treg cells in immune evasion mechanisms is evident from various experimental
tumor models, where depletion of these cells or modulation of their function significantly
improved the therapeutic efficacy of the vaccines (36, 96-98).

Blocking antibodies

against some of the signature costimulatory molecules expressed by Treg cells like
CTLA-4 and GITR were able to induce potent antitumor immunity and this was
associated with increased number of tumor-specific interferon-y-secreting CD4+ and
CD8+ T cells in the spleen (98, 99). Strikingly, a combination of blocking antibodies
against both CTLA-4 and GITR synergistically enhanced anti-tumor responses and was
able to eradicate more advanced tumors in mice (98). Tumors are known to suppress
immunity by promoting the chemokine mediated recruitment followed by cytokine
mediated expansion, and activation of Treg cells (100). This specific recruitment of Treg
cells results in the inhibition of effector T cell activation, immune escape, and ultimately
tumor progression (3). Interestingly, many tumors are known to produce cytokines such
as IL-I0 and TGF -~, which promote the proliferation of nTreg cells, and as well as the
conversion of CD4 T cells into iTreg cells (3, 101, 102). Conversion of naive CD4+
T cells into iTreg cells and their accumulation in tumor sites (5, 103) also playa key role
in obstructing tumor immunosurveillance and cancer immunotherapies (8, 103). In one
study,

it has

been

reported

that

cyclooxygenase

(COX)-2

and

its

product

prostaglandin play an important role in the pathogenesis of non-small cell lung cancer
(104). COX-2 along with its product, prostaglandin produced by tumors induced the
11

expression of FoxP3 in T cells, and consequently increased Treg cell activity in the tumor
(l05). Furthermore, inhibition of COX-2 reduced Treg cell frequency and activity in the
tumor and attenuated FoxP3 expression in tumor infiltrating lymphocytes along with
decreased tumor burden. The effective approach for cancer immunotherapy will depend
on the identification of unique cell surface receptors or ligands that can greatly enhance
the effector responses against cancer but also inhibit the suppressive function of Treg
cells and also conversion of naIve CD4+ T cells into iTreg cells. In this context, signaling
via the members of TNFR costimulatory molecules may have the potential to control the
function as well as generation of iTreg cells in settings of vaccines with potential
therapeutic efficacy.

iTreg cells and transplantation
In the last two decades transplantation of organs, tissues, or cells between genetically
non-identical individuals has become a routine therapeutic option for many disorders
such as organ failure, cancers and other hematological malignancies.

However,

transplantation of allogeneic tissue is associated with secondary diseases arising from
graft-versus-host (GVH), in case of bone marrow cell transplant or transplantation of
tissues rich in mature lymphocytes, or host-versus-graft (HVG), in case of all foreign
transplants, immune responses. These responses develop when immune cells of the graft
or recipient recognize allogeneic histocompatibility antigens and mount an immune
attack against the recipient or donor, respectively. During this activation, proliferation of
effector cells along with the release of proinflammatory cytokines result in tissue damage
(l06). The discovery of immunosuppressive drugs for the prevention of GVH and HVG

12

immune responses, paved the way for the clinical use of allogeneic transplantation as a
curative modality for treating various disease states.
Despite this accomplishment, GVH disease, graft rejection, and opportunistic
infections

due

to

transplantation remain

prolonged
the

nonspecific

major hindrance

imm~nosuppression

limiting the

efficacy

following

of allogeneic

transplantation. Studies show that allogeneic graft rejection (HVG) can be mediated by
host CD4+ and CDS+ T cells (107), NK cells (10S), NKT cells (109) and

yo T cells (110,

111) that can recognize histocompatibility antigens of the donor cells.

In order to

overcome this, patients are treated with immunosuppressive drugs such as calcinurin and
mammalian target of rapamycin (mTOR) inhibitors. Whereas, GVHD requires that the
graft contain immunocompetent cells before transplantation, and there must be
histocompatibility differences in antigens between host and the donor which will
ultimately lead to donor immune response to host. Both CD4+ and CDS+ T cells mediate
the effector pathway in the onset of GVHD and HVGD using multiple direct, such as
killing of target via mechanisms perforin and FasL (112), or indirect mechanisms, such as
proinflammatory cytokines, delayed type hypersensitivity reactions, generation of
humoral immunity.
To overcome complications associated with allogeneic transplantation and permit
engraftment, recipients and grafts undergo a series of conditioning procedures.

The

primary purpose of this conditioning is to suppress host immunity to prevent graft
rejection by reducing the immunocompetent cells. To this purpose, hosts are treated with
myeloablative drugs and total body irradiation that are cytotoxic in nature (113).
Following transplantation, recipients are treated chronically with immunosuppressive
agents to prevent graft rejection as well as control GVHD. Use of cytotoxic conditioning
13

and immunosuppressive drugs are often associated with toxicity and side effects reducing
the efficacy of transplantation and decreasing the overall survival (114). Therefore, the
development of novel immunosuppressive regimens with minimal/tolerable toxicity is of
critical importance and focus of the transplantation field.
The activities of Treg cells are now recognized as fundamental to the
development and maintenance of immune tolerance and shown to inhibit alloreactive Tcell activation and effector cell function (6, 115), serving as an attractive therapeutic tool
for inducing tolerance against transplanted grafts (116, 117). Despite decades of research
into the phenotypes and functions of different subsets of Treg cells, only recently have
they been sufficiently well characterized to begin considering how they might be targeted
therapeutically. There are numerous reports that by manipulating the numbers and/or
function of Treg cells in mice, we can decrease pathology in a wide range of contexts,
such as autoimmunity and transplantation. Transplantation in sublethally conditioned
mice along with donor Treg cell infusion was shown to prevent graft rejection and
suppress the onset of acute GVHD (30-32, 118, 119). Conversely, depletion of Treg cells
from either graft or recipients following transplantation enhances the rate of graft
rejection and development of GVHD (31, 118). Treg cells are present in relatively low
frequencies in lymphoid organs. For efficient use of Treg cells for inducing tolerance in
transplantation setting, studies have focused on developing strategies for both ex vivo and
in vivo expansion of Treg cells (7). In some settings, both ex vivo expansion of Treg cells

and subsequent activation of Treg cells to increases their suppressor cell potency was
shown to inhibit the onset of GVHD (119). Although expansion strategies that can target
in vivo expansion of Treg cells will be safer and clinically relevant, they remain to be

developed.
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Many transplantation protocols reqmre use of immunosuppressive agents like
calcineurin inhibitors cyclosporine A and mTOR inhibitor, rapamYClll.

These

immunosuppressive agents influence the Treg cell expansion strategies as they have both
negative and positive effects on Treg cells. For example, calcineurin inhibitors block the
production of IL-2, in tum reducing the Treg cell proliferation, function and expansion
due to their critical dependence on IL-2 (120). There the use of calcineurin inhibitors are
associated with nonspecific suppression of both Teff and Treg cells with the requirement
of continuous use in the patients with long-term adverse consequences. Therefore the use
of such nonspecific immunosuppressant has recently been called into question for the
ultimate goal of achieving clinical transplantation tolerance.

Therefore, there is an

intense interest in developing immunosuppressive drugs that preferentially inhibit the
function of Teff cells with no or positive effects on Treg cell development and function.
Rapamycin, a mTOR inhibitor, appears to suffice this promise.
Rapamycin is a potent immunosuppressant and an inhibitor of T cell proliferation.
It acts on a serine/threonine protein kinase (mTOR) that has

an important

immunomodulatory function in both innate and adaptive immune responses.

mTOR

plays a crucial role in cell growth and proliferation, transcription, translation, ribosomal
synthesis, and cytoskeleton organization (121). Rapamycin is produced by Streptomyces
hygroscopicus and was first identified as a potent antifungal agent (122). Later it was

found to exhibit potent immunosuppressive activity and inhibit cell proliferation. It is
currently used as an immunosuppressive drug in renal transplantation (123) and for the
prevention of graft rejection and GVHD in various transplantation settings (124, 125). It
is also used as a chemotherapeutic agent for treatment of various cancers (126).
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Unlike other immunosuppressive agents in the context of transplantation,
rapamycin has two fold advantage that it not only suppresses the proliferation of T cells,
but also helps the generation of iTreg cells and does not affect the proliferation of nTreg
cells (127), indicating that Treg cells are not prone to mTOR inhibition. Unlike other
immunosuppressive agents, rapamycin does not alter the immunosuppressive ability of
Treg cells in in vitro cultures (128).

In vivo administration of rapamycin results in

increased Treg cells numbers compared to CD4+ Teff cells (128, 129).

In addition,

rapamycin in combination with IL-2 was effective in selectively expanding Treg cells
from a mixed CD4+ T cell population in vitro (130). In another study, the observation
that stimulating CD4+ T cells in the presence of rapamycin results in induction of
suppressor functions in conventional CD4+ T cells offered an explanation that rapamycin
not only promotes survival and function of nTreg cells, but also induces FoxP3
expression in CD4+ T cells by converting them into iTreg cells (131). TGF -~ induces
FoxP3 expression through the activation of the transcription factor SMAD3 (mothers
against decapentaplegic homologue 3), which in combination with NF AT binds to the
enhancer region of FoxP 3, ultimately resulting in its transcription (132).

Under

physiological conditions, signaling through mTOR results in inhibition of SMAD3
activation in Teff cells (133), which can be inhibited by rapamycin, leading to the
activation of SMAD3 and expression of FoxP3. Now the cause of a generalized increase
in the frequency of Treg cells in the presence of rapamycin can be interpreted as a result
of two effects: 1) the ability ofnTreg cells to expand in the presence ofrapamycin, and 2)
the promotion of FoxP3 expression in CD4+ T cells. Rapamycin, therefore, is viewed as
a tolerogenic drug that can be used in combination with other therapeutic approaches in
transplantation and autoimmune diseases aimed at inducing Treg cells. Particularly, the
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ability of rapamycin to suppress the function of Teff cells not only is important for the
generation of a time window required for the generation of regulatory mechanisms, but
also serves to suffice the FDA requirement for the use of standard immunosuppression
for transplant patients. The dual ability of rapamycin to suppress the function of Teff
cells and facilitate the generation of Treg cells makes it as the drug of choice for
immunomodulation. Most importantly, rapamycin also has immunoregulatory functions
on antigen-presenting cells, such as DCs (134), further enhancing its use for the
generation of tolerance.

4-1BB/4-1BBL signaling pathway and immune regulation

The specificity of T cells responses are controlled by a series of orchestrated signaling
pathways.

First, the engagement of TCR with MHC/ Ag complex determines the

specificity of the immune response (135). However, other signals such as costimulation
(CD28-B7) and cytokines (IL-2) are required for full activation of T cells (135). In the
absence of these signals, T cells usually undergo antigen specific immune down
regulation, called anergy (136). After the initial activation, T cells go on and differentiate
into effector cells of which some will survive as long-lived memory T cells (137). After
the initial activation, T cells upregulate various members of the TNFR family
costimulatory molecules and uses signaling via these receptors for survival, proliferation,
expansion, and differentiation to acquire effector and long-term memory functions.
TNFR family members such as, CD27, CD134 (OX40), CD137 (4-1BB), HVEM,
CD30, FAS and GITR play a direct role in T cell responses leading to initial T cell
activation. TNFR members are divided into various groups based on the intracellular
domains or factors that are associated with these receptors. For example, receptors like
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FAS are associated with death domains (DD) and signaling through these receptors
activate the caspase cascade, ultimately leading to apoptosis (11). Importantly, some of
the TNFR members such as 4-1BB and OX40 are associated with TNF receptor
associated factors (TRAF) which play an important role in T cell activation, survival and
differentiation (11, 138, 139).
4-lBB (CDI37, TNFSFR9) is a member of the TNF receptor family which was
initially shown to play an important role as a costimulatory molecule for both CD4+ and
CD8+ T cells (140). 4-lBB is expressed on activated CD4+ and CD8+ T cells thereby
controlling their proliferation, survival and cytokine production (141, 142). Additionally,
this receptor is also expressed by activated NK cells, neutrophils, eosinophils, subsets of
immature/mature DCs in human as well as mice (136, 143-147). Its ligand, 4-1BBL is
expressed by activated professional APCs (143, 148, 149) as well as other non-immune
cells such as smooth muscle cells and endothelial cells (150). Thus, regulation of T cell
responses by 4-1BB signaling most likely occurs by the engagement of 4-1BBL on
activated APCs with 4-lBB on activated T cells, ultimately resulting the activation of T
cells, their survival, expansion, and conversion to effectors and long-term memory cells.
The engagement of 4-1 BBL with 4-1 BB may transduce the signal not only to T
cells for immune activation, but also reverse signaling into APCs with both positive
immune consequences. Reverse signaling through 4-1 BBL can occur in DC, B cells, and
monocytes (151, 152), suggesting the role of this signaling pathway on multiple cell
types with multiple functions. The role of 4-1 BBL reverse signaling is best illustrated in
human DCs where 4-1BBL cross-linked on DCs with CD137-Fc led to DC maturation in
a TNF -u dependent manner (153).

Reverse signaling of 4-1 BBL also up-regulated

chemokine receptor CCR7, thereby mediating the migration of DC. Finally, CD137L18

activated DCs were able to induce T cell differentiation and proliferation along with the
production of proint1ammatory cytokines IL-12 and IFN-y. Most importantly, a recent
report has demonstrated that reverse signaling converts human monocytes into functional
Des (154).

Collectively, these data demonstrate that the 4-1BB/4-IBBL signaling

system tunes the immune system at multiple effector cell types for the generation of
effector immune responses to cancers and infections.
The kinetics of 4-1 BB expression in vitro reveal that the expression on T cells
peaks at about 48 hr after primary T cell activation and declines again after 4-5
days (140, 155, 156). However, in vivo analysis of 4-lBB expression reveals that its
expression on T cells can be earlier, peaking at 12-36 hrs and is more transient as
compared to in vitro kinetics (157). This expression pattern coincides with the T cell
activation kinetics and fall between the expression of activation markers, CD69 and
CD44 (158). In addition to its role as an activation-induced costimulatory receptor on T
cells (156), 4-1 BB is also expressed constitutively on Treg cells (159, 160) with potential
function of regulating the balance between Teff and Treg cells with important
implications in health and disease.
The ability of costimulatory TNFR family members like 4-1 BB to regulate both T
cell and Treg cell activation, survival and differentiation at different stages in the immune
response make these molecules potential targets for various immunomodulatory
approaches for the treatment of various cancer and graft rejection and tolerance induction
to autoantigens. The potential of 4-1 BB as a target for immunomodulation in the cancer
setting arises from the findings that it can greatly enhance the expansion of CD4+ and
CD8+ T cells in vivo (14, 140, 158, 161) and its ability to make these cells to be
refractory to Treg cell mediated immunosuppression (12, 159). We recently showed that
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when 4-1 BBL was used as a component of vaccine against vanous tumor models
increased the number of both CD4+ and CD8+ T effector as well as memory responses
(15) along with a decrease in intratumoral Treg cells with therapeutic efficacy in various
tumor models. It is not clear at this point how 4-1 BB signaling leads to a better ratio of
Teff/Treg cells within the tumor and lymphoid organs.

Signaling via 4-1BB may

preferentially expand Teff cells, actively inhibit the generation of iTreg cells, and/or
preferentially cause Treg apoptosis. Regardless, our recently published studies in tumor
setting using 4-1BB costimulation as a means of immunomodulation are exciting and
further substantiate the importance of this pathway for modulating immune responses for
therapeutic purposes.
The potential use of 4-1 BB signaling as a target for immunotherapy in context of
transplantation and autoimmunity arises from the constitutive expression of 4-1 BB on
Treg cells and the ability of signaling via this receptor to effectively expand nTreg cells

ex vivo without losing their suppressive ability and FoxP3 expression (12, 162). Our
laboratory has recently demonstrated that sorted nTreg cells constitutively express 4-1 BB
receptor and respond to IL-2 by upregulating the level of this receptor (12).

Most

importantly, Treg cells were expanded over 110 fold within a few weeks by periodic
stimulation with low dose exogenous IL-2 and a chimeric form of 4-1BBL, SA-4-1BBL.
The expanded cells had potent suppressor function on Teff cells as demonstrated in vitro.
Importantly, adoptive transfer of the expanded Treg cells in a chemically diabetic
allogeneic islet model resulted in effective prevention of graft rejection and glucose
homeostasis (12). These findings along with the ability of rapamycin and IL-2 to expand
nTreg cells and/or convert naIve CD4+ T cells into iTreg cells led us to hypothesize that
targeting 4-1 BB in the transplantation and autoimmunity settings in the presence of
20

rapamycm may serve as a viable approach to expand Treg cells in vivo for
immunotherapy.
In conclusion, 4-1BB signaling has great potential as an immunomodulatory
approach to shift the balance between Teff and Treg cells for the treatment of diseases
that can benefit from a predominant form of one of these cell types. Therefore, the main
focus of this PhD study is to test the utility of 4-1 BB signaling for either expanding or
contracting Treg cell numbers in inverse correlation with the number of Teff cells with
the ultimate goal of treating cancer, autoimmuity, and graft rejection.
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Figure 1. Development of nTreg and iTreg cells_

nTreg cells are selected based on

TCR-MHC interactions in the thymus and migrate to periphery for the control of
autoimmunity. In marked contrast, iTreg cells are generated de novo in the periphery
from conventional naIve CD4+ T cells. Although the precise mechanism responsible for
the generation of iTreg cells is not well elucidated,

TGF-~

and IL-2 appear to be play

important roles. These Treg cells use various mechanisms to control the function of cells
of adaptive and innate immunity for the establishment of tolerance.

22

CD4+FoxP3+

CD4+FoxP3-

11 Tl'eg cells

=

T cells

!

0

:0

...
...-u

-'0

!

?4-1BBL

CD4+FoxP3+

llTl'eg cells
CD4+FoxP3+

iTl'eg cells

-.--...... :::=

+

4-1BBL

0

~

:0
~

.--...
;...

;...

:::

\Jj

0

~

CD4+FoxP3+

CD4+FoxP3+

iTl'eg cells

It Tl'eg cells

Tllrget cells

Figure 2. Pleiotropic effects of 4-1 BB signaling on the regulation of development and
function of nTreg and iTreg cells. The 4-1BB signaling contributes to the proliferation,
expansion, and/or survival of already existing nTreg and iTreg, but inhibits the
regulatory/suppressive function of these cells by endowing Teff cells resistant to
suppression by Treg cells. The effect of signaling via 4-1 BB on the generation of iTreg
cells is not known.
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Figure 3. Opposing functions of rapamycin on Treg and Teff cells. Rapamycin inhibits
the proliferation of activated CD4+ Teff cells through the inhibition of mTOR signaling
pathway which is crucial for proliferation, transcription, translation, ribosomal synthesis,
and cytoskeleton organization. Whereas rapamycin facilitates their conversion of
activated CD4+ Teff cells into iTreg cells without a deleterious effect on the survival and
expansion of iTreg and nTreg cells. Collectively, these effects result in tilting the balance
towards Treg cells with positive treatment consequences in transplantation and
autoimmune settings.
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CHAPTER 2
IMMUNOMODULATORY FUNCTION OF SA-4-1BBL ON
CONVERSION OF NAIVE CD4+ T CELLS INTO CD4+FoxP3+ T
CELLS

Introduction
Despite major breakthroughs in elucidating the effector mechanisms required for
effective tumor immunity, a number of immune evasion mechanisms employed by
cancers hinder the successful translation of mechanistic approaches into effective tumor
immunotherapy. Such evasion mechanisms include the ability of tumors to induce a
tolerogenic and immunosuppressive microenvironment and secretion of inhibitory factors
which act synergistically to counteract effector immune responses. One such mechanism
is the generation and/or preferential recruitment of Treg cells into the tumor or draining
lymphoid organs. Treg cells playa dominant role in cancer immune evasion mechanisms
as shown in various clinical (4, 94, 95, 163) as well as preclinical settings (2, 3). Tumors
modulate immune responses (2, 35, 95) either by recruiting and expanding preexisting
nTreg cells (164) and/or by converting naive CD4+FoxP3- T cells into iTreg cells (165168). These Treg cells then suppress anti-tumor immune responses by targeting cells of
innate, adaptive, and humoral immunity, such as CD4 and CD8 T lymphocytes, NK cells,
and B lymphocytes, ultimately leading to tumor progression (164, 169, 170).
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Although there are various types of T cells with regulatory functions, such as
CD4+FoxP3- IL-I0 secreting Tr1, CD4-CD8- T cells (171) as well as CD8+ Treg cells
(172, 173), CD4+FoxP3+ Treg cells appear to play the most dominant role for immune
regulation under normal physiological as well as disease settings. In humans and rodents,
Treg cells constitute 5-10% of CD4+ T cell population and can be divided into two
different types; natural and induced. Although processes involved in the generation of
nTreg cells in the thymus are well defined, those for iTreg cells are not as extensive but
include antigen, IL-2,

TGF-~

and retinoic acid (67, 174, 175).

TGF-~

mediated signals

are also required for the induction of iTreg cells that are differentiated by antigen from
naIve CD4 T cells in the periphery. Of critical significance to this study, tumors employ
some of these molecules for recruitment of nTreg cells or conversion of naIve CD4+ T
cells into iTreg cells for evading immune surveillance (2, 4, 176). Treg cells exert their
suppressive function either directly through cell-cell contact or through soluble factor.
Although the precise mechanism of suppression is still not clear, physical elimination
(177) and inhibiting IL-2 production (178) needed by effector T cells, induction of
regulatory DCs (179), inhibition of effector T cell proliferation through

TGF-~

(29) and

IL-IO (180) are some of the mechanisms used by Treg cells for exerting their suppressive
activity.
The importance of Treg cells, both nTreg as well as iTreg, in immune evasion
mechanisms employed by tumors has generated immense interest in efforts to reduce
number or function of these cells for therapeutic interventions (36, 98). Tumors employ
multiple mechanisms for evading T cell responses. Some of these include alterations of
components of the antigen presentation machinery, secretion of inhibitory factors,
activation of negative regulatory pathways, and recruitment of Treg cell populations (9026

93). Tumors are known to suppress immunity by promoting the chemokine mediated
recruitment followed by cytokine mediated expansion, and activation of Treg cells (100).
This specific recruitment of Treg cells results in the inhibition of effector T cell
activation, immune escape, and ultimately tumor progression (3). Treg cells represent
one of the most dominant immune evasion mechanisms employed by tumors for
progression. Increased numbers of Treg cells in tumor tissue and/or peripheral blood of
patients with various cancers have been reported (2, 4, 35, 94, 95) and this is associated
with poor prognosis and survival (2). Dominant role of Treg cells in immune evasion
mechanisms is evident from various experimental tumor models, where depletion of these
cells or modulation of their function significantly improved the therapeutic efficacy of the
vaccines (36, 96-98). Blocking antibodies against some of the signature costimulatory
molecules expressed by Treg cells like CTLA-4 and GITR were able to induce potent
antitumor immunity and this was associated with an increased number of tumorspecific interferon-y-secreting CD4+ and CD8+ T cells in the spleen (98, 99). Strikingly,
a combination of blocking antibodies against both CTLA-4 and GITR synergistically
enhanced anti-tumor responses and was able to eradicate more advanced tumors in mice
(98).
Interestingly, many tumors are known to produce cytokines such as IL-I0 and
TGF-~,

which promote the proliferation of nTreg cells as well as the conversion of CD4

T cells into iTreg cells (3, 101, 102).

Conversion of naive CD4+ T cells into iTreg

cells and their accumulation in tumor sites (5, 103) also playa key role in obstructing
tumor immunosurveillance and cancer immunotherapies (8, 103). In one study, it has
been reported that cyc100xygenase (COX)-2 and its product prostaglandin, play an
important role in the pathogenesis of non-small cell lung cancer (104). COX-2 along
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with its product, prostaglandin, produced by tumors induced the expression of FoxP3 in T
cells, and consequently increased Treg cell activity in the tumor (105).

Furthermore,

inhibition of COX-2 reduced Treg cell frequency and activity in the tumor and attenuated
FoxP3 expression in tumor infiltrating lymphocytes along with decreased tumor burden.
Signaling through TNFR family members play an important role in the activation,
proliferation, survival, and differentiation of both CD4+ and CD8+ Teff cells (181).
Among the TNFR family members, 4-1BB has emerged as a key modulator ofCD4+ and
CD8+ T cell proliferation and survival. 4-1 BB is not constitutively expressed on T cells,
but rather induced upon T cell activation (182, 183).

Signaling through 4-1BB also

endows T effector cells to be refractory to suppression by Treg cells (Figure 2) (12, 14).
4-1BB ligation may exert multiple activities on both thymic (nTreg cells) and peripheral
(iTreg cells) regulatory T cells at several stages.

Ligation of 4-1BB promotes the

proliferation and/or survival of already existing nTreg and iTreg cells, but inhibit the
regulatory/suppressive function of these cells.

However, 4-1BBL activity on the

conversion of naIve CD4+ T cells to iTreg cells is not known.

We, therefore, hypothesized that 4-1 BB signaling can be exploited for the
development of therapeutic vaccines and generated a chimeric molecule, SA-4-1BBL,
with core streptavidin (SA) where the extracellular domain of the mouse 4-1BBL was
fused to C-terminus of SA. The SA portion of the molecule allows for oligomerization of
the chimeric protein that possesses pleiotropic effects on cells of innate, adaptive, and
regulatory immunity, which translate into therapeutic efficacy against cancer in various
preclinical settings (184). Importantly, we had previously demonstrated that SA-4-1BBL
co stimulation makes Teff cells to be refractory to suppression by Treg cells and increases
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the ratio of CD8+ Teff to Treg cells at the tumor site when used as the adjuvant
component of tumor associated antigen (TAA) based vaccines (184).

Given the

importance of iTreg cells in tumor immune evasion, we herein tested if SA-4-1BBL
co stimulation affects the conversion of Teff cells into iTreg cells. Our data demonstrate
that SA-4-1BBL effectively inhibits antigen- and

TGF-~-mediated

conversion of Teff

into Treg cells through induction of IFN-y produced in Teff cells.

Importantly,

immunomodulation with an SA-4-1BBL-based vaccine also blocks the conversion of
Teff into iTreg cells in a tumor setting in vivo. Collectively, these data demonstrate the
pleiotropic functions of SA-4-1BBL and its potential as an effective immunomodulator
for the development of therapeutic vaccines against cancer and chronic infections.

Materials and Methods
Mice and reagents

OVA-specific TCR-transgenic C57BLl6 OT-II (Rag-I) mIce were purchased from
Taconic Farms.
Jackson

C57BLl6.FoxP3.gfp and C57BLl6 mice were purchased from The

Laboratory.

OT-II.FoxP3.gfp

mIce

were

generated

by

crossmg

C57BLl6.FoxP3.gfp with OT-II (Rag-I-) mice. OT-ILFoxP3.gfp (CD45.1/2) mice were
generated by crossing C57BLl6.FoxP3.gfp (CD45.2) with OT-ILSJL (CD45.1) mice.
C57BLl6 4-1BB

-1-

mice were kindly provided by Dr.

A.T.

Vella of University of

Connecticut, Farmington, CT, with permission from Dr. B.S. Kwon of University of
Ulsan, Korea. OT-II 4-1BB-1- mice were generated by crossing C57BLl6 4-1BB-1- mice
with OT-II (Rag-I-). Mice were maintained under specific pathogen-free conditions at the
University of Louisville (Louisville, KY) and used at the age of 8-10 weeks. This study
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was reviewed and approved by the Institutional Animal Care and Use Committee of the
University of Louisville, and animals were cared for in accordance to institutional and
National Institutes of Health guidelines. OVA peptide (aa 323-339) was purchased from
AnaSpec, Inc, Fremont, CA.
CD4+ T cell sorting
I

Spleen and lymph nodes from OT-II (Rag- -J or OT-II 4-1BB

·f-

or OT-II.FoxP3.gfp mice

were harvested and processed into single cell suspension, and RBCs were lysed using
ACK solution. For sorting CD4+CD2Y T cells from OT-II or OT-II 4-1BB-f - mice, cells
were stained with CD25-PE and CD4-APC for 30 mins at 4°C. Cells were washed and
resuspended in HBSS media at a concentration of 5x10 6/ml in FACS tubes. For sorting
CD4+FoxP3.gfp- T cells from OT-II.FoxP3.gfp cells were stained with CD4-PE alone for
30 mins at 4°C. Cells were washed and resuspended in HBSS media at a concentration of
5 x 106/ml in FACS tubes. Cells were sorted using a FACSVantage and FACSAria cell
sorters (Figure 4) (BD Biosciences, San Jose, CA). In some experiments, sorted cells
were labeled with 0.251lM CFSE before using them for in vitro cultures.
Preparation of APCs

For the preparation of APCs, spleen and lymph node cells from naIve C57BLl6 mice
were depleted for T cells by first staining with anti

a~- TCR

Ab (clone H57 -597) for 30

mins. Cells were washed and incubated with Low-Tox-M rabbit complement (Cedarlane
Laboratories, Burlington, NC) for 60 min at 37°C for the lysis of T cells. After several
washes with PBS, the live cells were irradiated with 2,000 cGy and used as APCs in
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co culture experiments with sorted OT-II CD4+CD25- T cells or OT-II CD4+FoxP3.gfp- T
cells. Cells were checked for T cell depletion using flow cytometry (Figure 4).
In vitro T cell cultures and phenotyping

5xl0 5 cells/ml of sorted naive CD4+CD25- T cells from OT-II or OT-II.4-1BB-I- mice or
CD4+FoxP3.gfp- T cells from OT-II.FoxP3.gfp mice were plated in 96 well plate with
2xl0 6 cells/ml ofT cell depleted APCs from C57BLl6 to a final volume of200!J.1. Cells
were cultured with varying doses of (0.05 - 0.5!J.M) OVA peptide (OVA323-339) and
cultured in complete MLR media for 4 days.
Construction, expression, purification and characterization of SA-4-1 BBL is
previously described (185).

To some cultures, SA-4-1BBL (10!J.g/ml) or equimolar

concentration of SA (2.4!J.g/ml) as control and varying amounts (0 - 2ng/ml) of
recombinant human

TGF-~1

(PeproTech) were also added.

Cultured cells were

phenotyped using CD4 APC (Clone RM4-5) or CD4 PE (Clone GK1.5), CD25 PE or
CD25 PE-Cy7 (Clone PC61). Intracellular FoxP3 staining was performed to cells that are
not transgenic for EGFP according to the manufacturer's protocol (eBioscience, San
Diego, CA).

Isotype Abs with matched fluorochromes were used as controls.

All

samples were collected using FACSCalibur or BD LSR II (BD Biosciences) and analyzed
using FlowJo (Tree Star) or FACS Diva software respectively.
For some in vitro experiements, culture supernatants were collected and analyzed
for cytokines using a BD Cytometric Bead Array (CBA) Mouse Thl/Th2/ThI7 Cytokine
Kit (BDbiosciences) according to the manufacturer's protocol and analyzed using FCAP
Array software (Soft Flow, Inc, St. Louis Park, MN).
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In vivo Tumor experiment

C57BLl6.SJL (CD45.l) mice were challenged s.c. in the right flank with 3 x 106 live
OVA expressing EG.7 tumor cells. When the tumor size reached 9-10 mm in diameter,
3-4xl06 sorted CD4+FoxP3.gfp- cells from OT-II.FoxP3.gfp (CD45.1I2) mice were
adoptively transferred by intratumoral injection (Figure 8a). Mice were vaccinated one
day later intratumorally with 25 /lg SA-4-1BBL or equimolar SA (control) protein.
Spleen, draining and non-draining LNs, and tumor were harvested 5 days after
vaccination and processed into single cell suspension as previously described (184).
Cells were stained with CD45.l-PE, CD45.2-APC, CD4-Alexa 700 and CD25-PE-Cy7
and analyzed using flow cytometry.
Confocal Microscopy for detection of intra-tumor iT reg cells

Detection of FoxP3.gfp expressed by iTreg cells in the tumor using confocal microscopy
requires unique tissue processing.

During regular tissue processing for confocal

microscopy, EGFP molecules lose their florescence ability in tissue sections or in cells
that have lost membrane integrity (186). Therefore, fixation of tumor tissue is required
before processing. Furthermore, these same fixation procedures must maintain the tissue
structure so that the ability to detect other cell surface molecules by immunofluorescence.
Briefly, for tumor confocal microscopy and efficient gfp (FoxP3) green florescence, each
tumor were dissected into half and before any other procedures, tissues was fixed by
immersion in 4% paraformaldehyde containing 10% sucrose for 24hrs at room
temperature (RT) (186). Fixed tissue was embedded in OCT, and snap-frozen above
liquid nitrogen. Frozen tissue blocks were stored at -70°C and 5 micrometer sections
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were cut and placed on slides. Slides were dried at R T overnight, and then stained with
DAPI antibody.

Five-micrometer sections were stained with DAPI and analyzed for

DAPI and gfp (FoxP3) using confocal microscopy.

Statistical analysis
Comparisons between two groups were performed using Student's t-test with Microsoft
Excel software. For each test, P values less than 0.05 considered significant. Data are
represented as mean ± SD.

Results

SA-4-1BBL inhibits antigenic conversion
NaIve CD4+CD2Y T cells have been shown to convert into iTreg cells under low dose of
antigenic stimulation (165, 167). The first evidence of in vivo conversion by foreign
antigens came from a study where mice treated with low doses of antigen cross-linked to
DEC-205 Ab (targets antigens specifically to DCs) and delivered by osmotic pump.
Conversion of CD4+CD2Y T cells into iTreg cells was also shown in another adoptive
transfer model where sorted CD4 cells were transferred into irradiated mice (72). Under
these lymphophenic conditions, these cells readily underwent conversion and this was
independent of thymus; but was dependent of CD28 signaling. Similarly, OVA-specific
naIve T cells from T/B monoclonal mice (17/9 DO 11.1 0 RAG }-I-) converted into
FoxP3+ iTreg cells when mice were administered with chicken ovalbumin through oral
route (83). Based on these studies, protocols have been developed for in vitro generation
of iTreg cells using low doses of a given antigen (187).
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In vitro generation of iTreg cells reqmres both TCR stimulation and the
cytokines TGF-~ is absolutely required for naYve CD4+ effector cells to convert into iTreg
cells. During TCR-stimulation, addition ofTGF-~ to naive CD4+ T cells cultures induces
the expression of FoxP3 (66). Low dose antigenic conversion is known to depend on
TGF-~

signaling and conditions that prevent activation of APCs as well as IL-2

production by naIve T cells (67). Conversion mediated by antigenic stimulation is
dependent on the accumulation of AP-I signaling molecule that can interact with TCR
activated NF AT (188). Both AP-l and FoxP3 are known to compete for NF AT binding.
During subimmunogenic TCR stimulation, lesser availability of AP-l is known to
facilitate the binding of NF AT to FoxP 3gene locus thereby promoting the expression of
FoxP3 and generation of iTreg cells (189). Thus, TCR signaling is important in the
generation of iTreg cells.
To investigate the effect of SA-4-1 BBL on low dose antigen-driven conversion,
we cultured naYve CD4+CD2S- T cells transgenic for OVA323-339 with T cell-depleted
APCs and varying doses of OVA323-339 peptide ranging from O.OS - O.S/lM in the
presence or absence of exogenous SA-4-1BBL (Figure Sa). After 4 days of culture,
cultures were stained with CD4-APC, CD2S-PE-Cy7 and FoxP3-PE, and analyzed using
multiparameter flow cytometry by gating on CD4+ live T cells. There was an antigen
dose-dependent increase in cell division as assessed by CFSE dilution (Figure Sa).
Upregulated expression of both CD2S and FoxP3 was seen when sorted naIve CD4+ T
cells were cultured with lower rather than higher doses of antigen (Figure Sb, upper row).
Importantly, co stimulation mediated by SA-4-IBBL actively shifts the balance towards
an effector phenotype which is evident by the decrease in FoxP3+ to FoxP3- ratio (Figure
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5b, bottom row). Addition of SA control protein did not affect the rate of conversion and
were comparable to cultures which only received different doses of antigen (Figure 5b,
middle row). SA-4-1 BBL co stimulation also significantly inhibited the absolute number

of CD4+ FoxP3.gfp+ T cells generated as compared with untreated controls at any given
dose of antigen (Figure 5d).

To further test whether this inhibition of conversion is exclusively mediated by
signaling through 4-1BB ligand, we cultured naIve CD4+CD2Y T cells from OT-II 4IBB-1- mice with lowest dose of antigen where the conversion rate was higher.

This

effect was SA-4-1BBL specific and required 4-1BB signaling since 4-1BB KO cells
treated with SA-4-1BBL had similar levels of FoxP3+ T cells as compared with untreated
control cells (Figure. 5c).

Collectively, these data demonstrate that costimulation

mediated by SA-4-1BBL antagonizes the low dose antigenic stimulus required for the
conversion of naIve CD4 + T cells into iTreg cells.

SA-4-1BBL inhibits TGF-p mediated conversion
TGF-~ along with TCR stimulation converts peripheral CD4+CD25- naive T cells to

iTreg cells by induction of transcription factor FoxP3 (69, 166, 167).

TGF-~

induces

FoxP3 expression through the activation of the transcription factor SMAD3 which in
combination with TCR induced NFAT binds to the enhancer region of FoxP3 ultimately
resulting in its transcription (132). The findings that 4-1 BB stimulation under low dose
of antigen appeared to inhibit the conversion of CD4 T cells into FoxP3 expressing Treg
cells prompted us to further investigate the activity of 4-1 BB signaling on

TGF-~

mediated iTreg generation. To this purpose we used a higher dose of antigen where we
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do not see the effect of antigen driven conversion (Figure Sa). Stimulating naIve CD4+
FoxP3.gfp- T cells at higher dose of antigen (O.SIlM) in the presence of exogenous

TGF-~

resulted in FoxP3+ iTreg cells in a dose dependent manner (Figure 6a, upper row). A
blocking Ab to TGF -~ totally blocked the generation of iTreg cells, demonstrating the
specificity of TGF -~-mediated conversion (Figure 6b).

Consistent with the low-dose

antigenic stimulation, SA-4-1 BBL costimulation significantly inhibited the

TGF-~

mediated conversion as assessed by percent as well as absolute number of CD4+
FoxP3.gfp+ T cells generated as compared with SA treated or untreated controls (Figure
6a, b). Collectively, these results demonstrate that signaling through 4-1 BB on activated
T cells can suppress the expression of FoxP3 in the presence of exogenous

TGF-~.

Cytokine milieu established by 4-1BB signaling control the conversion
It has been demonstrated by various studies that signaling through OX40, another TNFR

family costimulatory member, results in the inhibition of both low dose antigen as well as
TGF-~ mediated conversion of naIve CD4+CD2Y T cells into iTreg cells (190,191). One

study showed that signaling through OX40 induces memory T cells and IFN-y produced
by these memory T cells inhibit TGF-~ mediated conversion of naIve CD4+T cells into
iTreg cell (192). In a different model, another study has shown that OX40 induced IFNy, IL-6 and IL-4 block the generation of iTreg cells from naIve CD4+ T cells

During T cell activation signaling through 4-1 BB is shown to promote the
secretion of differentiating cytokines such as IFN -y and IL-4 (181), but the role of these
cytokines in the generation of iTreg cells is not clear.

We analyzed the culture

supernatants for various Thl/Th2/Th17 cytokines using cytometric bead array.
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It

revealed that 4-1 BB stimulation significantly increased the production of IFN -y but not
IL-4, IL-6 and IL-17 (Figure 7a). To determine to what extent these cytokines playa role
in SA-4-1BBL mediated inhibition of Treg conversion, blocking Abs against IFN-y and
IL-4 at varying doses were added to the cultures containing

TGF-~

and SA-4-1BBL.

Addition of 5!!g/ml of a-IFN-y Ab to cultures stimulated with SA-4-1BBL partially
rescued the conversion of naIve CD4 T cells into Treg cells mediated by

TGF-~

(Figure

7b). Importantly, addition of 25!!g/ml a-IFN-y Ab to the cultures significantly increased
the frequency of FoxP3+ T cells completely abolishing the effect of 4-1BBL as shown by
the percentage as well as the absolute number of CD4+FoxP3.gfp+ T cells (Figure 7b, c).
We could not totally rescue the absolute number of CD4+FoxP3.gfp+ T cells by adding
25!!g/ml a-IFN-y Ab as compared to

TGF-~

alone (Figure 7c), which might be due to

secondary effects of blocking a-IFN-y Ab. We saw a decreased live cells (data not
shown) when we added antibodies to the cultures. Due to this decreased live cells in the
cultures, we compared the ratios of Teff cells versus iTreg cells and found that SA-4IBBL decreased the absolute number of CD4+FoxP3+ cells as compared to CD4+FoxP3cells and this effect was reverted when we added 25!!g of IFN-y to the cultures (Figure
7d). Consistent with our cytokine quantitative data (Figure 7a), addition of a-IL-4 Ab to
cultures stimulated with SA-4-1BBL had no effect on the conversion of naIve CD4 T
cells into Treg cells (Figure 7b, c).

Collectively, these results indicate that IFN-y

stimulated by 4-1BB signaling playa major role in inhibiting TGF-ji mediated Treg
converslOn.
SA-4-1BBL inhibits tumor mediated conversion

Treg cells, both naturally occurring and induced, playa dominant role in tumor immune
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evasion mechanisms as demonstrated by a series of clinic (193) and preclinical studies
(164, 168, 194). Importantly, most tumors express high levels

ofTGF-~,

and as such can

actively convert tumor-specific T effector cells into iTreg cells as an effective means of
immune evasion (195). We, therefore, tested if the observed immunomodulatory effect
ofSA-4-1BBL on iTreg conversion can be translated in vivo in the OVA expressing EG.7
tumor model (Figure 8a). In this context, we first determined whether established EG.7
OVA tumors can convert adoptively transferred naIve CD4+FoxP3.gfp- cells from OTII.FoxP3.gfp mice into CD4+FoxP3.gfp+ cells. As expected, control SA injected mice
converted CD4+FoxP3.gfp- cells into CD4+FoxP3.gfp+ cells significantly in spleen
(Figure 8b) and to a lesser extent in the draining LN (dLN) (Figure 8c). Similar to the in
vitro data, mice vaccinated with SA-4-1BBL readily blocked the tumor mediated

conversion as evident by the decrease in the percentage of CD4+FoxP3.gfp+ cells in
spleen and dLN (Figure 8b, c). Although, we observed high levels of iTreg cells in tumor
draining LNs as compared with SA-treated controls, this difference did not reach
statistical significance. This effect was also seen within the tumor microenvironment as
significantly lower number of FoxP3.gfp+ cells were evident in tumors of mice vaccinated
with SA-4-1BBL as compared to SA control tumors (Figure 9a, b). Confocal microscopy
further showed that SA-4-1BBL blocks the accumulation of FoxP3.gfp+ T cells in the
tumor as compared to SA control tumors. Taken together, these results demonstrate that
immunomodulation with SA-4-1BBL is effective in preventing the conversion of
CD4+FoxP3.gfp- T effector cells into CD4+FoxP3.gfp+ iTreg cells in a tumor
microenvironment. These results are consistent with and provide a plausible mechanistic
insight into our recently published studies demonstrating that vaccination with SA-41BBL and HPV E7 T AA showed potent therapeutic efficacy established TC-l tumors
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that was associated with the production of high levels of IFN-y and a higher intratumoral
CD8+ Teff/Treg ratio (196).

Discussion
Signaling through 4-1 BB receptor plays a critical role in modulating not only
adaptive, but also innate and regulatory immunity as demonstrated by us (184, 185) and
others (197-200), and as such may have important therapeutic implications in settings of
autoimmunity, cancer, and chronic infections. In the context of regulatory immunity,
signaling via 4-1BB receptor may have diverse and opposing consequences.

For

example, we (185) and others (199, 200) have previously demonstrated that signaling via
4-1 BB on naturally occurring Treg cells serves to expand them in vitro in the presence of
exogenous IL-2. However, Treg cells have no suppressive function in the presence of the
ligand since signaling via 4-1 BB on T effector cells endows these cells to be refractory to
inhibition by Treg cells (185) via yet to be defined mechanisms.

Although, the

physiological consequence of the expansion of nTreg cells via 4-1 BB signaling during
the course of an immune response is not obvious, it may serve as an alternative
mechanism to activation induced cell death for achieving immune homeostasis after an
antigenic challenge andlor preventing extensive collateral damage by controlling the
function of expanded Teff cells. This outcome may be regulated by transient interaction
between 4-1BBL inducible expressed on APCs with 4-1BB on Treg and Teff cells. The
present study reveals another important and novel function of 4-1 BB signaling on
regulating the balance between adaptive and regulatory immunity, i.e., blocking the de
novo generation of iTreg cells from Teff cells through IFN-y production. Therefore, the

triple function of 4-1 BB signaling on T cells to i) enhance activation of naIve T cells,
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survival, and differentiation into long-term memory with a Thl response (184) ii) endow
Teff cells to be refractory to inhibition by Treg cells (185), and iii) inhibit the conversion
of Teff cells to iTreg cells, reported in the present study, may have important implications
for the treatment of cancer that exploits Treg cells for immune evasion (164, 170) and
requires a Th 1 dominated response for immunotherapy (196). These features are not
unique to 4-1BB as OX-40, another member of the TNFR superfamily, has similar effects
in regulating the balance between Teff and Treg cells with the exception that it directly
blocks the inhibitory function of Treg cells via the down regulation of FoxP3 expression
(201, 202). Similar to our finding with 4-1BB, OX-40 also utilizes IFN-y to block the
conversion of Teff cells into iTreg cells (190,191,203) even though there are reports that
OX-40 induced IL-4 and IFN-y (190) or in combination with IL-6 (203) are required for
this function.

The likely cause for such a discrepancy can be attributed to different

culture systems used. Given the preferential effect of signaling via OX-40 on CD4+ and
4-1 BB on CD8+ T cell function (204) and the importance of both of these cell types for
the generation of effective immune responses, a combinatorial use of agonists for these
two receptors for immunomodulation bears significant therapeutic potential for cancer
and chronic infections.
4-1BB signaling is known to promote cell division, survival, and cytokine
production.

The downstream molecules and their transcribed products that are

upregulated by 4-1BB signaling might negatively regulate transcription of FoxP3 that is
mediated by TGF-~ signaling. Current study indicate that cytokines such as IFN-y
produced from 4-1BB signaling may be important for suppressing FoxP3 expression,
essentially providing a mechanism for suppressing iTreg cell generation. The source of
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IFN-y produced in these cultures is mainly from sorted naive CD4+ cells stimulated with
antigen, but not from APCs as we did not detect any IFN-y in the culture supernatants
containing APCs alone (data not shown). This suggests that increased IFN-y produced by
SA-4-1BBL stimulated CD4+ cells acts in an autocrine fashion serving as an inhibitor of
FoxP3 expression.
It is presently unknown how IFN-y produced by 4-IBB signaling might interfere

with the induction ofFoxP3 in antigen-stimulated naIve T cells. IFN-y might act either
directly or indirectly on multiple signaling pathways that are required for the FoxP3
expression. First, naIve CD4 T cells give rise to Thl, Th2, Th17, and iTreg populations,
mainly promoted in a cytokine-dependent manner which in tum regulates various
lineage-specific transcription

factors

like

T-bet, GATA-3,

RORyt,

and FoxP3,

respectively (205). Interestingly, recent data found that Th 1 and Th2 lineage-specific
cytokines like IFN-y, IL-12 and IL-4 and the transcription factors they upregulate (T-bet
by

IFN-y

and

expression (206).

IL-12; GATA-3 by IL-4),

act

as

strong

suppressors

of FoxP3

Thus, it is possible that IFN-y induced by 4-1BB signaling might

indirectly promote to upregulation of T-bet. T-bet may in tum suppress
transcription ofFoxP3.

TGF-~

mediated

Second, prolonged TGF-~ receptor signaling is necessary to

maintain intracellular FoxP3 (79, 207), which might be due to the requirement for DNA
demethylation and epigenetic modification at the FoxP3 promoter site. This suggests that
upstream or downstream signals from the

TGF-~

signaling like SMAD3, might be the

primary targets of suppression by IFN-y signaling pathway. Third, it has been recently
shown that TGF -~ signaling was found to promote upstream demethylation of
the FoxP3 gene, thereby enhancing FoxP3 expression. Even though the exact mechanism
of this process is unknown, it is speculated that this might be mediated by
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TGF-~

signaling mediated suppression of a DNA methyltransferase (208). Inhibiting the

TGF-~

mediated suppression of DNA methyltransferase might also serve as an alternate target
for INF-y antagonism on FoxP3 expression.
In conclusion, previous studies have shown that signaling via 4-1BB on nTreg
cells can expand them in vitro (12, 162,209) as well as endows Teff cells to be refractory
to inhibition by Treg cells (185).

In the current study, we have shown that 4-1BB

signaling also inhibit the conversion of Teff cells to iTreg cells through the production of
INF-y. Although, the physiological consequence of these contradicting functions of 41BB signaling during the course of an immune response is not obvious, it may serve in
achieving immune homeostasis. 4-1BB signaling on Teff cells might help in mounting
an effective immune response to pathogens while simultaneously expanding Treg cells.
Once pathogen is cleared, the expanded Treg cells can then regulate the function of Teff
cells to control extensive collateral damage.
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Figure 4. Outline of in vitro conversion of naIve CD4+ T cells into FoxP3+ T cells.
Briefly, sorted CD4+CD2Yor CD4+FoxP3.gfp- cells were cultured with T cell depleted
APCs in the presence of OVA323-339 peptide (0.05 to 0.75IlM),

TGF-~

(0.1 to 2ng/ml),

SA-4-1BBL and SA as control. Cells were analyzed after 4 days of culture using flow
cytometry.
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Figure 5. 4-1BBL inhibits the conversion of naIve CD4 T cells into CD25+PoxP3+ T
cells.

A, In vitro CD4+ T cell CPSE cell division. Flow sorted CD4+ T cells were

stimulated for 4 days with various doses of OV A323-339 peptide in the presence of
irradiated C57BL!6 T cell depleted APCs. CFSE dilution was analyzed using flow
cytometry by gating on CD4+ cells. B, naIve CD4+ CD2Y T cells from wild type OT-II
transgenic mice were cultured with APCs (T cell depleted) and with various doses of
OVA323-339 peptide (upper row) in the presence of SA- 4-1BBL (bottom row) and
equimolar SA (middle row) as control. After 4 days, CD25 and intracellular FoxP3 were
evaluated by gating on CD4+ T cell population using flow cytometry.

Data is

representative of at least three independent experiments. C, as in B, naIve CD4+ CD2ST cells from 4-1 BB"/- OT -II transgenic mice were cultured with O.05IlM of OV A323-339
peptide with (bottom row) or without (upper row) SA- 4-1 BBL and FoxP3 and CD25
expression was accessed by gating on CD4+ T cells. D, Absolute number of CD4+PoxP3+
T cells generated from cultures as in B. Data is representative of at least three
independent experiments with similar results.
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Figure 6. 4-IBBL suppresses expression of FoxP3 induced by exogenous

TGF-~.

A,

naIve CD4+FoxP3.gfp- T cells from OT-II.FoxP3.gfp mice were cultured with T cell
depleted APCs and

O.5~M

OVA323-339 with different doses of exogenous

TGF-~

in the

presence (lower row) or absence (upper row) of SA-4-IBBL or with equimolar
concentration of SA (middle row) as control.

At day 4, CD25 and EGFP (FoxP3)

expression in CD4+ T cells was analyzed using flow cytometry. Data is representative of
at least three experiments. B, C, as in A were cultured and analyzed after 4 days of
stimulation for total number (B) or percentage (C) of live CD4+FoxP3.gfp+ cells
generated.

a-TGF-~

neutralizing antibody was used as control. Data are mean ± SD and

are representative of at least three independent experiments with similar results.
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Figure 7. 4-1BBL suppression of FoxP3 induction is mediated by IFN-y. A, naIve
CD4+FoxP3.gfp' T cells from OT-II.FoxP3.gfp mice were cultured with T cell depleted
APCs and O.5)lM OVA323-339 with exogenous
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TGF-~

(2ng/ml) with or without 4-1BBL

(lOllg/ml) and 4 days later, culture supernatants were analyzed for levels of various
cytokines. B, as in A, naIve CD4+FoxP3.gfp- T cells from OT-ILFoxP3.gfp mice were
cultured in the presence or absence of varying doses of IFN -y or IL-4 blocking
antibodies. At day 4, CD25 and EGFP (FoxP3) expression in CD4 T cells was analyzed
using flow cytometry. C, absolute number ofCD4+FoxP3.gfp+ T cells from B. D, ratio of
the absolute number of CD4+FoxP3.gfp- cells versus CD4+FoxP3.gfp+ from the cultures
as in B.
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Figure 8. SA-4-1BBL blocks the accumulation ofCD4+FoxP3.gfp+ T cells in spleen and
dLN.

A.

Schematic diagram of in vivo tumor experiment.

B, C, sorted naIve

CD4+FoxP3.gfp- T cells (CD45.1I2+; 4 x 106) were injected intratumorally into tumor
bearing C57BLl6.SJL (CD45.1 +) mice.

On the next day, mice were vaccinated

intratumorally with SA-4-IBBL (25 /lg) or equimolar SA control protein. Transferred
cells were assessed from spleen (B) and draining LNs (C) 5 d after vaccination by gating
on CD4+CD45.112+ cells using flow cytometry.

Data are mean ± SD and are

representative of two independent experiments with at least 3 animals per group.
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Figure 9. SA-4-1BBL blocks the accumulation of CD4+FoxP3.gfp+ T cells within the
tumor.

A, confocal microscopic images of tumor tissue showing intracellular gfp

(FoxP3, green) and DAPI (blue). B, absolute number of cells from more than three areas
per donor sample from three independent donor samples per group counted from the
confocal images. Control tumors did ·not receive CD4+FoxP3.gfp- cells and served as a
background for gfp (FoxP3) staining.
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CHAPTER 3
IMMUNOMODULATORY FUNCTION OF SA-4-1BBL AND
RAPAMYCIN ON iTreg CELL GENERATION

Introduction
Allogeneic transplantation rejection is associated with activation and proliferation
of effector cells that, along with the release of proinflammatory cytokines, result in tissue
damage (106). The activities of Treg cells are now recognized as fundamental to the
development and maintenance of immune tolerance and shown to inhibit alloreactive Tcell activation and effector cell function (6, 115) serving as an attractive therapeutic tool
for inducing tolerance (116, 117). Numerous reports targeting Treg cells showed that by
manipulating the numbers and/or function of Treg cells can decrease pathology in a wide
range of contexts, such as autoimmunity and transplantation in preclinical models.
Allogeneic graft rejection is initiated and perpetuated primarily by T cells that
respond to allogeneic MHC molecules via direct and indirect recognition pathways (210).
The importance of T cells in allograft rejection is demonstrated by the acceptance of
allogeneic grafts by nude mice primarily deficient in T cells. Furthermore, most of the
immunosuppressive drugs used in clinical transplantation to control graft rejection are
targeted at T cells.

After recognition of allogeneic antigens via TCR, T cells get

activated, proliferate, expand, and acquire effector functions that not only directly inflict
damage to the graft but also initiate a senes of other effector mechanisms, such as
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proinflammatory and humoral, that ultimately results in the destruction of the graft.
Therefore, various immunosuppressive drugs have been developed that target various
aspects of T cells activation and effector functions for the control of graft rejection. Most
protocols use a combination of agents in a chronic fashion to achieve this goal. Although
successful in preventing allograft rejection, the chronic use of these non-specific
immunosuppressive drugs not only has direct toxic effects on the host and the graft, but
also increases the risk of opportunistic infections and cancer due to a compromised
Immune response. Therefore, the ultimate goal of the transplantation field is to develop
tolerogenic regimens that prevent graft rejection in the absence of immunosuppression
while preserving immunocompetence. Although many current transplantation protocols
require the use of immunosuppressive agents that targets calcineurin and mTOR
pathways, a preference is developing towards specifically targeting the mTOR pathway
for not merely the control of acute rejection, but also induction of tolerance in
combination with regimens that are designed to achieve this goal.

In this context,

rapamycin emerged as the drug of choice.
Unlike other immunosuppressive agents that are designed to suppress Teff cells,
rapamycin has several advantages as it not only effectively suppress Teff cells by
arresting them in the cell cycle (211), but also facilitate the conversion of these cells into
iTreg cells (120), (127). In addition, rapamycin does not negatively affect the activation
and proliferation of nTreg cells. Importantly, rapamycin has been shown to change the
behavior of DCs into a tolerogenic one.

Collectively, these pleiotropic effects of

rapamycin have the potential to induce tolerance in the absence of continuous use of
nonspecific generalized immunosuppression. A series of studies have provided direct
evidence for the pleiotropic effects of rapamycin on immune responses in preclinical and
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clinical settings. Inhibition of mTOR activity in mice causes marked decrease in T cell
proportion in the periphery (211). Extended use of rapamycin administration blocks the
conversion of thymocytes from double-negative (CD4-CD8-) to double-positive (CD4+
CD8+) T cells in the thymus (212), thereby interfering with the development of Teff cells
and potentially nTreg cells. Although rapamycin decreases the absolute number of T
cells in the periphery, it does not alter the proportion of CD4+FoxP3+ Treg cells in the
periphery (127). This indicates that the nTreg cell population is unaffected by mTOR
blockade mediated by rapamycin. Recent evidence suggests that FoxP3 expression in T
cells is negatively regulated by the PI3K-AKT-mTOR pathway, which is shown by the
blockade of FoxP3 upregulation in the presence of constitutive AKT activation (213).
This suggest that rapamycin mediated blockade of mTOR will yield higher proportion of
CD4+ cells that have upregulated expression ofFoxP3.
Treg cell function and homeostasis are not affected by rapamycin as compared to
its effect on Teff cells. Mouse or human Treg cells exposed to rapamycin in vitro have
normal suppressive function on Teff cell proliferation (128). This is not the case when
other immunosuppressive agents, such as calcineurin inhibitor cyclosporin A, are used
(214, 215).

In addition, extended administration of rapamycin in vivo results in a

decrease in the absolute numbers of all T cells in face of an increase in the number of
Treg cells (127, 129,215). These preclinical observations also apply to clinical settings
as it was shown that patients who received kidney transplants when treated with
rapamycin have a marked increase in the frequency of Treg cells as compared with total
CD4+ T cell numbers (129, 216).
TGF-~ converts CD4+CD2Y T cells into FoxP3 expressmg iTreg cells in the

presence ofTCR stimulation and IL-2 (217).
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The observation that both

TGF-~

and

rapamycin mediate the expression of FoxP3 in T cells led to investigations focused on
common signaling pathways involved, especially the mTOR pathway. The induction of
FoxP3 transcription by

TGF-~

depends on the activation of the transcription factor

SMAD3, which in combination with TCR signal activated NF AT , binds to the enhancer
region of FoxP3 and initiate the transcription of this gene (132). T cells that are not
treated with rapamycin, signaling through the mTOR pathway can inhibit the activation
of SMAD3, thereby downregulating the expression of FoxP3 (133). The blockade of
mTOR pathway by rapamycin leads to the activation ofSMAD3 that in tum binds FoxP3
gene, upregulate its expression, and thereby converting Teff cells into iTreg cells. These
aspects of rapamycin, therefore, qualify this drug as immunomodulatory component of
therapeutic approaches targeting the induction of transplantation tolerance. For example,
by using rapamycin in conjunction with blocking antibodies against CXC-chemokine
receptor 3 (CXCR3) and its ligands (CXCL9, CXCLIO and CXCLll) that are important
for effector T cell recruitment, increased the survival rate of islet as well as heart allograft
(218).
The synergetic activity of rapamycin with signal 3, i.e.

IL-2 or

TGF-~,

in

expanding Treg cells or converting Teff cells into iTreg cells, suggests that rapamycin
may be used in combination with signal 2 agents, such as costimulatory molecules of
TNF family, to change the Teff:Treg balance in favor of Treg cells for the induction of
transplantation tolerance.

TNFR costimulatory molecules play an important role in

regulating innate, adoptive and regulatory arms of the immune system. Costimulatory
receptor 4-1 BB is constitutively expressed on Treg cells and ligation of 4-1 BB is
effective in expanding these cells without loss oftheir immunosuppressive function (162,
209). The 4-1BB expression on Treg cells may be advantageous for increasing their
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expansion or survival in the context of transplantation, provided that the positive impact
of this signaling on Teff cells is simultaneously inhibited. In this context, rapamycin as
an immunosuppressive drug known to preferentially block the cycling of Teff cells
without a negative effect on Treg cells generation, proliferation, and effector function
emerges as the immunosuppressive drug of choice (127, 128, 130,219). Importantly, the
positive effect of rapamycin on the conversion of conventional CD4+ T Cells into iTreg
cells under TCR stimulation without impairment of their potent immunosuppressive
activity (131, 220), provides additional incentive as the drug of choice and justifies the
combinatorial use of 4-1 BBL and rapamycin for the induction of tolerance.
We, therefore, conducted a series of in vitro studies as a prelude to in vivo
tolerance induction efforts to test if 4-1BB co stimulation works in synergy with
rapamycin TCR stimulation and IL-2 to block the proliferative function of Teff cells and
convert these cells into iTreg cells.

Our data demonstrate that 4-1 BBL stimulation

induces the proliferation of Teff cells and rapamycin effectively block this proliferation
for the generation of iTreg cells.

Material and Methods
Mice and reagents

C57BLl6 and BALB/c mice were purchased from Jackson Laboratories or bred in our
animal facility.

Mice were maintained under specific pathogen-free conditions at the

University of Louisville (Louisville, KY) and used at the age of 8-10 weeks. This study
was reviewed and approved by the Institutional Animal Care and Use Committee of the
University of Louisville, and animals were cared for in accordance to institutional and
National Institutes of Health guidelines.
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CD4 T cell sorting from C57BL/6 or C57BL/6 4-1BB mice

Spleen and lymph nodes from C57BLl6 or C57BLl6 4-1 BB

-/-

mice were harvested and

processed into single cell suspension, and RBCs were lysed using ACK solution. For
CD4 cell sorting, cells were stained with CD25-PE, and CD4-APC. NaIve CD4+CD25- T
cells were sorted using a FACSVantage and FACSAria cell sorters (BD Biosciences).
Sorted cells were >95% pure.
Preparation of APCs from BALB/c

For the preparation of APCs, spleen and lymph node cells from naIve BALB/c mice were
depleted for T cells by first staining with anti

ap- TCR Ab (clone H57 -597) for 30 mins.

Cells were washed and incubated with Low-Tox-M rabbit complement (Cedarlane
Laboratories, Burlington, NC) for 60 min at 37°C for the lysis of T cells. After several
washes with PBS, the live cells were irradiated with 2,000 cGy and used as APCs in
coculture experiments with sorted C57BLl6 or C57BLl6 4-1BB

-/-

+

CD4 T cells. Cells

were checked for T cell depletion using flow cytometry (Figure 4).
In vitro T cell cultures and phenotyping

5xl05 cells/ml of sorted naIve CD4+CD2Y T cells from C57BLl6 or C57BLl6 4-1BB-/mice were plated with 2 x 106 cells/ml of T cell depleted APCs from BALB/c in the
presence of varying concentration of rapamycin and cultured in complete MLR media for
4 days. SA-4-1BBL (lOllg/ml) or equimolar concentration of SA (2.4llg/ml) as control
and rIL-2 were also added to the cultures. Cultured cells were phenopyped using CD4
APC (Clone RM4-5) or CD4 PE (Clone GKl.5), CD25 PE or CD25 PE-Cy7 (Clone
PC6l).

IntracellularFoxP3 staining was performed according to the manufacturer's
57

protocol (eBioscience). Isotype Abs with matched fluorochromes were used as controls.
All samples were collected using FACSCalibur or BD LSR II (BD Biosciences) and
analyzed using FlowJo (Tree Star) or FACS Diva software respectively.

Results
Rapamycin and IL-2 work in synergy to generate iTreg cells from alloreactive
CD4+ Teff cells

Given that IL-2 is required for the generation of iTreg cells, we first assessed the ability
of various doses of rapamycin in combination with IL-2 on the growth and differentiation
of naive CD4+ T cells and their conversion into iTreg cells in an allogeneic setting. To
this purpose, sorted CD4+ T cells were stimulated with irradiated allogeneic APCs in the
presence or absence of IL-2 and varying doses of rapamycin. Under normal allogeneic
setting or in the presence of rapamycin, irrespective of its dose, we did not observe
enhancement of the generation of CD25+FoxP3+ iTreg cells (Figure 10).

In marked

contrast, rapamycin significantly increased the percentage of CD25+FoxP3+ Treg cells in
the presence of IL-2 (Figure 10). However, Treg proportions were reduced by higher
dose of rapamycin (Figure 10). In conclusion, adding lower dose of rapamycin in the
presence of IL-2 was advantageous in increasing the overall nwnber of CD25+FoxP3+
iTreg cells.

4-1BBL in the presence of IL-2 and rapamycin further increases the generation of
CD2S+FoxP3+ iTreg cells from Teff cells

Since the IL-2 and low dose of rapamycin preferentially generated iTreg cells and these
cells express 4-1BB receptor, we next tested if costimulation with SA-4-1BBL further
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Improves the efficacy of this regImen

In

further generating/expanding iTreg cells.

Addition of SA-4-1BBL alone without IL-2 to allogeneic cultures in the presence of
rapamycin significantly increased the proportion of iTreg cells in these cultures (Figure
11). More importantly, the combination of 4-1BBL, IL-2, and rapamycin had the most
potent effect on the generation/expansion of iTreg cells (Figure 11). We also noticed that
addition of rapamycin to the cultures significantly reduced the percentage of
CD4+FoxP3+ T cells expressing CD25, indicating that rapamycin preferentially blocks the
proliferation of allogeneic CD4+ effector cells (Figure 11). Taken together, these data
demonstrate that the provision of three signals (allogeneic TCR stimulation, 4-1 BBL
mediated co-stimulation, and IL-2 cytokine) in the presence of rapamycin is an effective
and clinically applicable approach that effectively increases the generation/expansion of
iTreg cells.

4-1BB, but not CD28 signaling, is crucial for rapamycin mediated increase in the
generation/expansion of iTreg cells

Co stimulation via CD28 is critical for the generation ofnTreg cells. We, therefore, tested
if this costimulatory signal also has similar effects on the generation of iTreg cells in the
presence of rapamycin and how this effect compares with 4-1BB costimulation.

To

compare the ability of CD28 versus 4-1 BB co stimulation to increase the rapamycin/IL-2mediated generation of iTreg cells, we added anti-CD28 stimulating antibody to the
cultures containing rapamycin and IL-2. To our surprise, CD28 costimulation was not
able to enhance the generation of iTreg cells in the cultures containing rapamycin and IL2 (Figure 12). This data suggest that only 4-1 BB, but not CD28, signaling is efficacious
in generating iTreg cells in synergy with rapamycin and IL-2.
59

Discussion
When we cultured naIve CD4+ T cells in an allogeneic setting in the presence of
rapamycin, we observed two major effects. First, in order for rapamycin to convert these
cells into CD25+FoxP3+ iTreg cells, IL-2 is absolutely required.

Rapamycin through

mTOR inhibition is thought to skew towards the conversion of CD4+ T cells into iTreg by
increased usage of the STAT5 pathway over the PI3K pathway in response to IL-2 (221)
and in tum IL-2 receptor dependent STA T5 activation is required for FoxP3 transcription
(222). Thus, the rapamycin mediated mTOR inhibition in the presence of IL-2 signaling
favors the conversion/expansion of iTreg cells.

The second effect of rapamycm

IS

decrease in the proliferation of these

CD4+FoxP3- T cells which correlates with decreased number of cells expressing CD25.
The addition of rapamycin to the expansion culture was required for outgrowth of
converted iTreg cells at the expense of Teff cells.

Prior reports indicated that 4-1 BB signaling can expand Treg cells without losing
their suppressive activity (12).

Our data clearly demonstrate that in the absence of

rapamycin, signaling through 4-1BB actually promoted the proliferation of CD4+FoxP3T cells. This is consistent with the previous studies showing that signaling through 41BB promotes the proliferation, survival and function of effector CD4+ and CD8+ T cells
(12, 140). Importantly, 4-1 BB signaling in the presence of rapamycin and IL-2 clearly
increased the rapamycin converted iTreg cell as we observed higher percentage of cells
expressing FoxP3 when cultures were added SA-4-1BBL along with rapamycin and IL-2
as compared to rapamycin or rapamycin and IL-2 cultures.
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It has been recently reported that CD28 signaling plays a crucial role in the

development of Treg cells (9, 48) and these cells can be expanded in vitro using TCR and
CD28 stimulation (223). Moreover, CD28 signaling acts earlier than 4-1 BB due to its
constitutive expression on naive CD4 T cells.

We compared the ability of CD28

signaling to 4-1BB in expanding the rapamycin converted iTreg cells. We observed that
4-IBB but not CD28 co stimulation is effective in increasing the CD2S+FoxP3+ T cell
proportion in the cultures.

This suggests that 4-1 BB delivers quantitatively or

qualitatively different signals as compared to CD28 that allow expansion of rapamycin
and IL-2 mediated iTreg cells.

The observed difference between 4-1 BB and CD28 signaling might be due to
differential expression kinetics and signaling pathways used by these costimulatory
molecules. During conventional T cell activation, mTOR signaling integrates the TCR
and CD28 signals to transit from GO to G 1 phase of the cell cycle which requires
activation of NFAT (TCR induced), mitogen-activated protein kinases (MAPKs), API
(CD28 induced) and nuclear factor-KB (NF-KB) (224). The coordinated activity of these
factors determines the expression of many genes that are involved in cell cycle
progression along with the expression of IL-2 and IL-2 receptor. Whereas, 4-1 BB
signaling in the presence of TCR signal leads to activation of JUN N-terminal kinase
(JNK), API, MAPKs, ERK, NF-KB and NFAT. These molecules are involved in
promoting the production of IL-2, IL-4, IL-S and IFN-y. Costimulation through both
CD28 as well as 4-1BB results in the production of IL-2 and signaling through IL-2
receptor in tum activates mTOR through the PI3K-AKT-mediated signaling pathway
which ultimately lead to G 1 to S phase progression. So, both costimulatory molecules
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indirectly use the mTOR pathway for promoting cell cycling. In the current study, we
block the mTOR pathway using rapamycin, but still see an increase in the FoxP3 iTreg
cells when we add SA-4-1BBL but not a-CD28 activating antibody. The reason for this
observed discrepancy might be due to other signaling pathways that might be involved or
used by 4-1BB signaling in promoting the expression of FoxP3. Another reason for this
differential effect of CD28 and 4-1 BB signaling might lie in the expression kinetics of
CD28 and 4-1 BB. CD28 and 4-1 BB are expressed at various time points during the
activation of T cells. CD28 is constitutively expressed on T cells and acts initially during
the T cell activation. Whereas, 4-1 BB is expressed later after T cell and CD28
stimulation, and is only induced on T cells after activation. Further signaling studies on
these two costimulatory molecules and the factors they recruit will shed more light on the
differential effects we have observed in this study.

In conclusion, we have shown that low dose of rapamycin in the presence of IL-2
signaling promotes the conversion of naIve CD4+ T cells into iTreg cells.

4-1 BB

signaling further promotes the expansion of iTreg cells in a synergistic manner.
Furthermore, CD28 signaling did not promote the expansion of iTreg cells in contrast to
4-1 BB signaling. These data not only have important implications for inducing Treg cells
in transplantation setting, but also provide novel insights into the biologic effects of 41BBL on Treg cell expansion.
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Figure 10. Lower dose ofrapamycin in the presence ofIL-2 is effective in increasing the

CD25+FoxP3+ T cell proportion. NaIve CD4+ CD2Y T cells from C57BLl6 mice were
cultured with BALB/c APCs (T cell depleted) and with various doses of rapamycin (1
nM and 10 nM) in the presence or absence of IL-2 (25 U/ml). After 4 days, cells were
evaluated for CD25 and intracellular FoxP3 by gating on CD4 population using flow
cytometry. Data is representative of at least two independent experiments.
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Figure 11. Synergy between SA-4-1BBL and IL-2 in increasing the CD25+PoxP3+ T
cell proportion in the presence of low dose of rapamycin. NaIve CD4+ CD25- T cells
from C57BLl6 mice were cultured with BALB/c APCs (T cell depleted) and with or
without rapamycin (l nM) in the presence or absence oflL-2 (25 U/ml), and SA-4-1BBL
(lO )lg/ml) or in combination.

After 4 days, cells were evaluated for CD25 and

intracellular FoxP3 by gating on CD4 population using flow cytometry. Cells from with
and without rapamycin cultures were also stained for isotype antibodies for CD25 and
FoxP3 and gating was adjusted according to the isotype quadrants. Data is representative
of at least three independent experiments.
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+

+
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4-1 BB but not CD28 co stimulation is effective

+

III

increasing the

CD25+PoxP3+ T cell proportion. NaIve CD4+ CD2Y T cells from C57BLl6 mice were
cultured with BALB/c APCs (T cell depleted) and with rapamycin (1 nM) in the presence
or absence ofIL-2 (25 U/ml). SA-4-1BBL (10

~g/ml)

or anti-CD28 Ab (10

~g/ml)

were

also added to the culture with or without IL-2. After 4 days, cells were evaluated for
CD25 and intracellular PoxP3 by gating on CD4 population using flow cytometry. Data
is representative of at least two independent experiments.
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CHAPTER 4
CONCLUSIONS AND FUTURE PERSPECTIVES

Signaling through TNF receptors play a critical role in modulating adaptive,
innate and regulatory immunity with important therapeutic implications in settings of
autoimmunity, transplantation, cancer, and chronic infections.

In the context of

regulatory immunity, signaling via 4-1BB receptor may have diverse and opposing
consequences and can modulate the development and activity of regulatory T cells. For
example, we (185) and others (199, 200) have previously demonstrated that signaling via
4-1BB on naturally occurring Treg cells serves to promote their proliferation and/or
survival in vitro in the presence of exogenous IL-2. However, signaling via 4-1BB on T
effector cells antagonizes the suppressive function of of Treg cells thereby endowing
these cells to be refractory to inhibition by Treg cells (185) via yet to be defined
mechanisms. Although, the physiological consequence of these opposing effects of 4IBB signaling during the course of an immune response is not obvious, it might serve as
a homeostatic mechanism dictated by the expression kinetics, expression profile on
various cells and the availability of 4-1 BB and its ligand. This outcome may be regulated
by transient interaction between 4-1 BBL inducible expressed on APCs with 4-1 BB on
Treg and Teff cells in the course of ongoing immune responses.

The present study

reveals another important and novel function of 4-1 BB signaling on regulating the
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balance between adaptive and regulatory immunity. First, when 4-1BBL was used under
low dose antigenic stimulation or in the presence of TGF -~, it blocked the de novo
generation of iTreg cells from naIve T cells. Importantly, in the presence of rapamycin,
4-1 BB signaling played an opposing role by augmenting the conversion of Teff cells into
iTreg cells.
Inhibition of the conversion of naIve CD4+ T cells to iTreg cells or augmentation
of conversion of Teff cells into iTreg cells mediated by 4-1 BB signaling poise this
pathway with significant potential for therapeutic interventions in setting where Teff and
Treg cells serve as major culprit of the disease. As shown in Fig. 13, cancer suffers from
increased number of Treg cells and decreased number of Teff cells that also serve as a
major barrier for the success of immunotherapeutic interventions. Therefore, modulation
of 4-1 BB signaling using a well defined approach with the efficacy of effectively
reversing this balance will have desired therapeutic implications. In marked contrast, in
the setting of transplantation and autoimmunity where the excess of Teff cells perpetuate
the disease, reversing the balance of Teff:Treg in favor of Treg cells by exploiting 4-1 BB
signaling will serve an important therapeutic application. However, given the pleiotropic
effects of 4-1 BB signaling in the immune system, a better understanding of mechanistic
basis of how 4-1 BB signaling affects various cells of the immune system and the
conditions that will allow a controlled manipulation of these effect for therapeutic ends
will be required to maximize the efficacy over toxicity.
Accumulating evidence has shown that interaction between 4-1 BB and 4-1 BBL
plays an important role in controlling T cell function and immune regulation. There are
still great gaps in our knowledge regarding the activity, expression characteristics and
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involvement of 4-1 BB signaling on vanous cell types and at vanous stages of the
immune response during infections. In the case of Treg cell based immunomodulation for
treatment of cancer and autoimmunity, it is important to know the signaling
consequences of 4-1BB in controlling the expression of FoxP3. It is also important to
know the effect and nature of 4-1BB signaling on the proliferation, survival, and
regulatory function of both nTreg as well as iTreg cells and different mechanisms and the
signaling utilized by these cells for suppression. Without first understanding how nTreg
and iTreg cells suppress, it will not be possible to fully understand the differential effects
of 4-1BB signaling on various subsets of Treg cells as well as Teff cells. Another issue
that needs to be resolved is whether there are functional differences between nTreg and
iTreg cells, and the stability of FoxP3 expression on these cell types. It is also important
to exploit the receptors that are constitutively or inducibly expressed by Treg cells, and
what role these receptors play in the function of these cells.

More studies are are

required to show the importance of the balance between Teff to Treg cell during various
immune responses and disease settings. Further research will provide new information
regarding the potential usefulness of 4-1 BB co stimulation in different therapeutic
settings.
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Figure 13. Schematic diagram showing the possible roles played by Treg cells in various
disease setting and potential interventions by targeting Treg cells. (1) Under normal
physiological conditions, Treg cells are required in the periphery to control autoreactive
Teff cells as well as regulating the post-infection Teff cells. (2) In disease setting like
cancer and autoimmunity, abnormal function of Treg cells exacerbate the disease
condition. In case of cancer, Treg cells accumulate within the tumor and in the secondary
lymphoid organs as a result of tumor-mediated recruitment and/or expansion of
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preexisting nTreg cells or conversion of naive Teff cells into induced iTreg cells. Treg
cells then suppress anti-tumor immune responses by targeting cells of innate, adaptive,
and humoral immunity, thereby promoting tumor progression. In case of autoimmunity
and transplantation, lack of Treg cell number and/or function leads to excessive immune
response by auto-reactive or allo-antigen specific Teff cells, leading to tissue damage and
organ failure. (3) The goal of therapeutic interventions in case of cancers is to lower the
Treg cell number and/or function as well as inhibiting the conversion of naIve CD4+ T
cells to iTreg cells (shown in this study). This in tum will facilitate an effective Teff cell
response for eradication of tumors. This has important implications for the treatment of
cancer that exploits Treg cells for immune evasion and requires a Thl dominated
response for immunotherapy.

In the context of autoimmunity and transplantation,

increasing the Treg cell number and/or function and enhancing the rate of conversion of
CD4+ T cells into iTreg cells might be beneficial for the induction of transplantation
tolerance.
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